Add news
March 2010
April 2010
May 2010June 2010July 2010
August 2010
September 2010October 2010
November 2010
December 2010
January 2011
February 2011March 2011April 2011May 2011June 2011July 2011August 2011September 2011October 2011November 2011December 2011January 2012February 2012March 2012April 2012May 2012June 2012July 2012August 2012September 2012October 2012November 2012December 2012January 2013February 2013March 2013April 2013May 2013June 2013July 2013August 2013September 2013October 2013November 2013December 2013January 2014February 2014March 2014April 2014May 2014June 2014July 2014August 2014September 2014October 2014November 2014December 2014January 2015February 2015March 2015April 2015May 2015June 2015July 2015August 2015September 2015October 2015November 2015December 2015January 2016February 2016March 2016April 2016May 2016June 2016July 2016August 2016September 2016October 2016November 2016December 2016January 2017February 2017March 2017April 2017May 2017June 2017July 2017August 2017September 2017October 2017November 2017December 2017January 2018February 2018March 2018April 2018May 2018June 2018July 2018August 2018September 2018October 2018November 2018December 2018January 2019February 2019March 2019April 2019May 2019June 2019July 2019August 2019September 2019October 2019November 2019December 2019January 2020February 2020March 2020April 2020May 2020June 2020July 2020August 2020September 2020October 2020November 2020
News Every Day |

In new breakthrough, Moderna's COVID vaccine nearly 95% effective

WASHINGTON — US biotech firm Moderna on Monday announced its experimental vaccine against COVID-19 was almost 95 per cent effective, marking a second major breakthrough in the quest to end the pandemic.

Moderna released early results from a clinical trial with more than 30,000 participants, after American pharmaceutical company Pfizer and its German partner BioNTech last week said their vaccine was 90 per cent effective.

Both front-runners are based on new technology that uses synthetic versions of molecules called "messenger RNA" to hack into human cells and effectively turn them into vaccine-making factories.

"This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease," said Moderna CEO Stephane Bancel.

“Today’s news of a second vaccine is further reason to feel hopeful,” tweeted President-elect Joe Biden, but he cautioned that its widespread distribution was months away.

“Until then, Americans need to continue to practice social-distancing and mask-wearing to get the virus under control,” he said.

Moderna plans to submit applications for emergency approval around the world within weeks, and says it expects to have approximately 20 million doses ready to ship in the US by the end of the year.

The company, which has received $2 billion from the US government under “Operation Warp Speed,” added it is on track to manufacture between 500 million to a billion doses globally in 2021.

Global infections from COVID-19 have soared past 54 million with more than 1.3 million deaths since the virus emerged in China late last year.

President Donald Trump also weighed in on Twitter, to take credit: “Please remember that these great discoveries, which will end the China Plague, all took place on my watch!”

 

Beginning of the end?

 

Moncef Slaoui, who leads Operation Warp Speed, told MSNBC he hoped the two would be approved “somewhere towards in the first half of December”, with the Johnson & Johnson vaccine the next on the horizon early next year.

The Moderna vaccine, which was co-developed by the US National Institutes of Health, is given in two doses 28 days apart, and the preliminary results are based on the 95 of the 30,000 volunteers who fell ill with COVID-19.

Of the 95, 90 had been in the trial’s placebo group, and five in the group that received the drug, called mRNA-1273, translating to an efficacy rate of 94.5 per cent.

There were 11 people who fell severely ill, all of whom were in the placebo group.

A small fraction of people experienced severe symptoms such as fatigue, muscle and joint pains, or redness at the injection site, but these side-effects were short lasting.

“The light at the end of the tunnel just got even brighter,” tweeted Atul Gawande, a member of Biden’s coronavirus advisory board and a surgeon at a Harvard-affiliated hospital.

Crucially, Moderna also announced that its vaccine can remain stable at standard refrigerator temperatures of 2ºC to 8ºC for 30 days.

The company added it could be kept in long-term storage at standard freezer temperatures of -20ºC  for up to six months.

Pfizer’s vaccine, on the other hand, needs to be stored in deep-freezer conditions of -70ºC which could complicate supply chain logistics, particularly in less developed countries.

On the downside, Moderna’s vaccine has about three times more genetic material per dose than its Pfizer counterpart, Zoltan Kis, a research associate at Imperial College’s Future Vaccine Manufacturing Hub, said.

This would raise production costs and make it harder to scale-up.

 

Questions remain

 

The promising results of both vaccines are seen as a validation for mRNA technology, which has never before been brought to regulatory approval but has the potential to transform the field.

It is not yet clear how long lasting the protection will be from either the Moderna or Pfizer vaccines,  nor how well they work for the elderly, the age-group at highest risk from COVID-19.

Another open question is whether they stop people who are exposed to the virus from transmitting it on to the other people, even though they may be themselves protected from the disease.

Image: 
Section: 
Display Lead for: 
Home Page
Section
Agency: 
Image Position: 
Right



Read also

Nepal-India border points reopen

Asylum-seeker pupil who joined school as 15-year-old but ‘is balding and looks 40’ VANISHES after half-term

Police ‘refusing to hand dog stolen by travellers back to their owner’



News, articles, comments, with a minute-by-minute update, now on Today24.pro




Today24.pro — latest news 24/7. You can add your news instantly now — here